Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × Gemcitabine × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 32 Urinary Bladder Neoplasms 20 Lymphoma, Large B-Cell, Diffuse 14 Carcinoma, Non-Small-Cell Lung 13 Neoplasm Metastasis 12 Lung Neoplasms 11 Triple Negative Breast Neoplasms 9 Neoplasms 9 Carcinoma, Transitional Cell 8 Ovarian Neoplasms 7 Biliary Tract Neoplasms 7 Non-Muscle Invasive Bladder Neoplasms 6 Nasopharyngeal Carcinoma 6 Colorectal Neoplasms 6 Breast Neoplasms 6 Sarcoma 5 Recurrence 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Lymphoma 5 Fallopian Tube Neoplasms 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Ureteral Neoplasms 3 Lymphoma, Non-Hodgkin 3 Gastrointestinal Neoplasms 3 Gallbladder Neoplasms 3 Osteosarcoma 2 Nasopharyngeal Neoplasms 2 Melanoma 2

Interventions

Specimen Handling 11 Magnetic Resonance Spectroscopy 11 Cisplatin 8 pembrolizumab 7 Platinum 6 1,2-diaminocyclohexaneplatinum II citrate 6 Carboplatin 5 Biopsy 5 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Paclitaxel 4 Cetuximab 4 cemiplimab 3 Radiation 3 (225)Ac-DOTA-c(RGDyK) 3 ipatasertib 2 cabozantinib 2 Taxes 2 Pemetrexed 2 Nivolumab 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2 zipalertinib 1 tislelizumab 1 repotrectinib 1 relatlimab 1 peposertib 1 osimertinib 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06312137 2026-04-17

TroFuse-019

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡